Cancer Research Research Funding Cancer Genome no Abstract
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, A. S.
Right arrow Articles by Lattime, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, A. S.
Right arrow Articles by Lattime, E. C.
[Cancer Research 63, 2150-2157, May 1, 2003]
© 2003 American Association for Cancer Research

Immunology

Tumor-induced Interleukin 10 Suppresses the Ability of Splenic Dendritic Cells to Stimulate CD4 and CD8 T-Cell Responses1

Arvin S. Yang and Edmund C. Lattime2

Departments of Surgery and Molecular Genetics, Microbiology and Immunology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901

Dendritic cell (DC) maturation and function are influenced by the surrounding cytokine milieu. We demonstrate tumor-associated suppression of DCs in stimulating allogeneic and tumor-specific CTL and type 1 (IFN-{gamma}-producing) responses in both CD4- and CD8-positive T cells. DCs from MB49-bearing female mice fail to stimulate proliferative and IFN-{gamma}-producing responses in allogeneic mixed lymphocyte cultures. MB49 also inhibited DC function in stimulating type 1 responses against our tumor-specific antigen, the male antigen, HY. DCs from MB49-bearing male mice were unable to restimulate effective HY-specific CTLs or IFN-{gamma}. Tumor-induced interleukin (IL) 10 was found to be specifically responsible for DC dysfunction in response to antigenic driven maturation. This was demonstrated by restoration of DC function in splenic DCs from MB49-bearing female IL-10 knockout mice (HY disparity), whereas not in MB49-bearing male IL-10 knockout mice (no HY disparity). Finally, any tumor-induced systemic inhibitory effect on bone marrow precursors could be overcome by generation of bone marrow-derived DCs ex vivo. These bone marrow-derived DCs derived from MB49-bearing B6 mice were capable of inducing control levels of proliferation in allogeneic mixed lymphocyte reactions and a type 1 (IFN-{gamma}) cytokine profile. The BM-DCs were also capable of restimulating HY-specific CTL and IFN-{gamma} production. These studies reveal the tumor-associated in vivo effects of IL-10 inhibition on DC function in eliciting a type 1 immune response in both allogeneic and tumor-specific responses.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
P. A. Gonzalez, C. E. Prado, E. D. Leiva, L. J. Carreno, S. M. Bueno, C. A. Riedel, and A. M. Kalergis
Respiratory syncytial virus impairs T cell activation by preventing synapse assembly with dendritic cells
PNAS, September 30, 2008; 105(39): 14999 - 15004.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. A. Cohen, G. K. Koski, B. J. Czerniecki, K. D. Bunting, X.-Y. Fu, Z. Wang, W.-J. Zhang, C. S. Carter, M. Awad, C. A. Distel, et al.
STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells
Blood, September 1, 2008; 112(5): 1832 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Mocellin, F. M. Marincola, and H. A. Young
Interleukin-10 and the immune response against cancer: a counterpoint
J. Leukoc. Biol., November 1, 2005; 78(5): 1043 - 1051.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. L. Tourkova, G. V. Shurin, G. S. Chatta, L. Perez, J. Finke, T. L. Whiteside, S. Ferrone, and M. R. Shurin
Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides
J. Immunol., September 1, 2005; 175(5): 3045 - 3052.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. A Wallet, P. Sen, and R. Tisch
Immunoregulation of Dendritic Cells
Clin. Med. Res., August 1, 2005; 3(3): 166 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Liu, X. Bi, S. Xu, and J. Xiang
Tumor-Infiltrating Dendritic Cell Subsets of Progressive or Regressive Tumors Induce Suppressive or Protective Immune Responses
Cancer Res., June 1, 2005; 65(11): 4955 - 4962.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. S. Kang and P. M. Allen
Priming in the Presence of IL-10 Results in Direct Enhancement of CD8+ T Cell Primary Responses and Inhibition of Secondary Responses
J. Immunol., May 1, 2005; 174(9): 5382 - 5389.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Q. Li, A. L. Carr, E. J. Donald, J. J. Skitzki, R. Okuyama, L. M. Stoolman, and A. E. Chang
Synergistic Effects of IL-12 and IL-18 in Skewing Tumor-Reactive T-Cell Responses Towards a Type 1 Pattern
Cancer Res., February 1, 2005; 65(3): 1063 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Beckebaum, X. Zhang, X. Chen, Z. Yu, A. Frilling, G. Dworacki, H. Grosse-Wilde, C. E. Broelsch, G. Gerken, and V. R. Cicinnati
Increased Levels of Interleukin-10 in Serum from Patients with Hepatocellular Carcinoma Correlate with Profound Numerical Deficiencies and Immature Phenotype of Circulating Dendritic Cell Subsets
Clin. Cancer Res., November 1, 2004; 10(21): 7260 - 7269.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. P. Hussain, G. E. Trivers, L. J. Hofseth, P. He, I. Shaikh, L. E. Mechanic, S. Doja, W. Jiang, J. Subleski, L. Shorts, et al.
Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis
Cancer Res., October 1, 2004; 64(19): 6849 - 6853.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Ren, R. Strube, X. Zhang, S.-Y. Chen, and X. F. Huang
Potent Tumor-Specific Immunity Induced by an In vivo Heat Shock Protein-Suicide Gene-Based Tumor Vaccine
Cancer Res., September 15, 2004; 64(18): 6645 - 6651.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S.-J. Park, T. Nakagawa, H. Kitamura, T. Atsumi, H. Kamon, S.-i. Sawa, D. Kamimura, N. Ueda, Y. Iwakura, K. Ishihara, et al.
IL-6 Regulates In Vivo Dendritic Cell Differentiation through STAT3 Activation
J. Immunol., September 15, 2004; 173(6): 3844 - 3854.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
X. Chen, K. Doffek, S. L. Sugg, and J. Shilyansky
Phosphatidylserine Regulates the Maturation of Human Dendritic Cells
J. Immunol., September 1, 2004; 173(5): 2985 - 2994.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Avigan, B. Vasir, J. Gong, V. Borges, Z. Wu, L. Uhl, M. Atkins, J. Mier, D. McDermott, T. Smith, et al.
Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses
Clin. Cancer Res., July 15, 2004; 10(14): 4699 - 4708.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Loskog, H. Dzojic, S. Vikman, C. Ninalga, M. Essand, O. Korsgren, and T. H. Totterman
Adenovirus CD40 Ligand Gene Therapy Counteracts Immune Escape Mechanisms in the Tumor Microenvironment
J. Immunol., June 1, 2004; 172(11): 7200 - 7205.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Raina, S. Kharbanda, and D. Kufe
The MUC1 Oncoprotein Activates the Anti-apoptotic Phosphoinositide 3-Kinase/Akt and Bcl-xL Pathways in Rat 3Y1 Fibroblasts
J. Biol. Chem., May 14, 2004; 279(20): 20607 - 20612.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. A. Danna, P. Sinha, M. Gilbert, V. K. Clements, B. A. Pulaski, and S. Ostrand-Rosenberg
Surgical Removal of Primary Tumor Reverses Tumor-Induced Immunosuppression Despite the Presence of Metastatic Disease
Cancer Res., March 15, 2004; 64(6): 2205 - 2211.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Murillo, A. Arina, I. Tirapu, C. Alfaro, G. Mazzolini, B. Palencia, A. L.-D. De Cerio, J. Prieto, M. Bendandi, and I. Melero
Potentiation of Therapeutic Immune Responses against Malignancies with Monoclonal Antibodies
Clin. Cancer Res., November 15, 2003; 9(15): 5454 - 5464.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. S. Yang, C. E. Monken, and E. C. Lattime
Intratumoral Vaccination with Vaccinia-Expressed Tumor Antigen and Granulocyte Macrophage Colony-Stimulating Factor Overcomes Immunological Ignorance to Tumor Antigen
Cancer Res., October 15, 2003; 63(20): 6956 - 6961.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.